Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1982 • 10,605 citations

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 • 2,228 citations

Discrete stages of human intrathymic differentiation: Analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage

1980 • 1,668 citations

A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells. I. Production of anti-Tac monoclonal antibody and distribution of Tac (+) cells.

1981 • 1,366 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Characterization of a human B lymphocyte-specific antigen.

1980 • 1,098 citations

Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens.

1983 • 852 citations

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 • 737 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes.

1985 • 279 citations

Augmentation of the anti-tumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin 2.

1982 • 267 citations

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells.

1983 • 245 citations

The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2

1986 • 145 citations

Repetitive Weekly Cycles of Recombinant Human Interleukin-2: Responses of Renal Carcinoma With Acceptable Toxicity1

1988 • 139 citations

Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

1986 • 116 citations

Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.

1986 • 105 citations

Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial.

1987 • 87 citations

In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

1988 • 82 citations

The human lymphokine-activated killer cell system

1985 • 71 citations

Treatment of disseminated leukemia with cyclophosphamide and immune cells: tumor immunity reflects long-term persistence of tumor-specific donor T cells.

1984 • 67 citations

Clinical response of a patient with diffuse histiocytic lymphoma to adoptive chemoimmunotherapy using cyclophosphamide and alloactivated haploidentical lymphocytes. A case report and phase I trial

1985 • 30 citations

Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.

1984 • 22 citations

Potential Uses of Interleukin 2 in Cancer Therapy

1986 • 22 citations

Characterization of interleukin 2 (IL-2)-dependent cytotoxic T-cell clones

1984 • 19 citations

Effector mechanisms operative in adoptive therapy of tumor-bearing animals: implications for the use of interleukin-2.

1984 • 14 citations

Summary: potential of interleukin-2 for the therapy of cancer.

1984 • 11 citations

Status and potential of interleukin-2 for the treatment of neoplastic disease.

1987 • 10 citations

Clinical testing of IL-2: in vivo administration of IL-2 induces IL-2 dependent non-MHC-restricted cytotoxicity (NRC).

1987 • 6 citations